Eruptive Lentiginosis After Biologic Therapy Results and Literature Review in JDD
Have you read this latest article from the JDD? A new case report plus systematic review addresses eruptive lentiginosis as a form of post inflammatory pigmentary alteration in patients with psoriasis, highlighting a recently observed occurrence after ixekizumab therapy and summarizing the published evidence on risk factors and outcomes.
The authors present a 68 year old man with chronic plaque psoriasis who developed extensive eruptive lentiginosis following treatment with ixekizumab and review 26 articles identified through a PRISMA guided search. Reported cases span a broad range of Fitzpatrick skin types and treatment modalities, including phototherapy, conventional systemic agents, topicals, and biologics. The review considers potential mechanisms such as ultraviolet exposure and cytokine mediated melanocyte stimulation involving TNF alpha, IL 17, and IL 23, and notes a clinical course that often involves persistent pigmentation unlike other forms of post inflammatory pigmentary alteration. Treatment responses are variable and partial clearance with Q switched ruby laser is reported in some patients.
For practicing dermatologists and dermatology healthcare professionals interested in pigmentary sequelae of psoriasis or biologic therapy safety, this article consolidates case level data and discusses practical implications for counseling patients and selecting interventions. To examine the clinical images, case details, and the authors practical recommendations for diagnosis and management, consult the full JDD publication and consider how these findings align with your patient population and treatment protocols.
Blog write-up assisted by AI
